BOLD-100's Broad Potential Featured at the AACR Annual Meeting 2022

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in...

Related Keywords

Vienna ,Wien ,Austria ,Canada ,South Korea ,Vancouver ,British Columbia ,Mark Bazett ,Walter Berger ,Preclinical Development At Bold Therapeutics ,Bold Therapeutics Inc ,University Of Vienna ,Small Molecule Therapeutic Agents ,Medical University ,Anticancer Ruthenium Compound ,Metabolic Vulnerability ,Preclinical Development ,Bold Therapeutics ,